Fenbutrazate

Fenbutrazate is a pharmaceutical drug that was used as an appetite suppressant. It is a stimulant in the amphetamine family. Fenbutrazate was introduced in the 1960s by Janssen Pharmaceutica, a pharmaceutical company based in Belgium. It was sold under the brand name Pondinil.

Pharmacology

Fenbutrazate acts as a norepinephrine-dopamine reuptake inhibitor, meaning it increases the levels of the neurotransmitters norepinephrine and dopamine in the brain by inhibiting their reuptake into neurons. This leads to increased stimulation of the central nervous system, which can suppress appetite and increase alertness.

Medical Uses

Fenbutrazate was primarily used as an appetite suppressant in the treatment of obesity. It was also occasionally used off-label for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy due to its stimulant effects.

Side Effects

Common side effects of fenbutrazate include insomnia, dry mouth, nausea, dizziness, and anxiety. More serious side effects can include psychosis, dependence, and cardiovascular disease.

Legal Status

Fenbutrazate is currently a controlled substance in many countries due to its potential for abuse and dependence. It is classified as a Schedule II controlled substance in the United States under the Controlled Substances Act.

See Also

• Amphetamine
• Appetite suppressant
• Janssen Pharmaceutica
• Controlled Substances Act

Fenbutrazate Resources
Latest articles Most recent articles Ongoing trials	Wikipedia